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Abstract
Background: Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100) or
atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg, have not
been compared as initial antiretroviral treatment. To address this data gap, we conducted an open-
label, multicenter 48-week study (ALERT) in 106 antiretroviral-naïve, HIV-infected patients
(median HIV-1 RNA 4.9 log10 copies/mL; CD4+ count 191 cells/mm3) randomly assigned to the
FPV/r100 or ATV/r100 regimens.
Results: At baseline, the FPV/r100 or ATV/r100 arms were well-matched for HIV-1 RNA (median,
4.9 log10 copies/mL [both]), CD4+ count (mean, 176 vs 205 cells/mm3). At week 48, intent-to-treat:
missing/discontinuation = failure analysis showed similar responses to FPV/r100 and ATV/r100
(HIV-1 RNA < 50 copies/mL: 75% (40/53) vs 83% (44/53), p = 0.34 [Cochran-Mantel-Haenszel
test]); mean CD4+ count change-from-baseline: +170 vs +183 cells/mm3, p = 0.398 [Wilcoxon rank
sum test]). Fasting total/LDL/HDL-cholesterol changes-from-baseline were also similar, although
week 48 median fasting triglycerides were higher with FPV/r100 (150 vs 131 mg/dL). FPV/r100-
treated patients experienced fewer treatment-related grade 2–4 adverse events (15% vs 57%), with
differences driven by ATV-related hyperbilirubinemia. Three patients discontinued TDF/FTC
because their GFR decreased to <50 mL/min.
Conclusion: The all-QD regimens of FPV/r100 and ATV/r100, plus TDF/FTC, provided similar
virologic, CD4+ response, and fasting total/LDL/HDL-cholesterol changes through 48 weeks.
Fewer FPV/r100-treated patients experienced treatment-related grade 2–4 adverse events.
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Background
The protease inhibitors fosamprenavir (FPV) and atazana-
vir (ATV) both have pharmacokinetic characteristics sup-
porting their use once-daily (QD) boosted by small,
subtherapeutic doses of ritonavir [1,2]. Mini-dose ritona-
vir inhibits CYP3A4 metabolism of APV (to which FPV is
converted) and ATV, thereby decreasing their clearance,
raising their plasma concentrations and exposure, and
increasing their elimination half-lives [3]. To date, ritona-
vir 200 mg QD has been the recommended boosting dose
for FPV QD regimens [4]. COL10053 showed that this
dose provides a mean plasma APV concentration at the
end of a dosing interval (Cτ) of 1.4 μg/mL [5], which is
over 9-fold above the mean APV protein binding-adjusted
50% inhibitory concentration (IC50) for wild-type virus
(0.146 μg/mL) [6] and 4-fold above the historical Cτ value
observed with unboosted FPV 1400 mg BID (which, in
turn, is 2-fold higher than the IC50 for wild-type virus) [4].
Ritonavir 100 mg QD is the only boosting dose recom-
mended for use with ATV 300 mg [7]. This dose increases
the ATV minimum plasma concentrations (Cmin) and area
under the plasma concentration-time curve (AUC) 5-fold
and 3-fold higher, respectively, than can be attained with
unboosted ATV 400 mg QD [8].
As the incidence of gastrointestinal (GI) adverse events
and unfavorable lipid elevations is directly proportional
to the magnitude of ritonavir dose [3], using the lowest
ritonavir dose possible for PI boosting would be expected
to incur the fewest tolerability problems. With FPV, sev-
eral pharmacokinetic studies that have evaluated a low
ritonavir boosting dose of 100 mg QD reported that it
provides a mean or median steady-state APV Cmin 6- to 13-
fold higher than the protein binding-corrected 50%
inhibitory concentration (IC50) for wild-type HIV (0.146
μg/mL) [6], and that patients may experience better GI
tolerability and less elevation in lipids [5,9-12].
As no study to date has compared the long-term efficacy
of all-QD FPV/r100 and ATV/r100 regimens, we con-
ducted a clinical trial evaluating their relative efficacy/
safety in combination with QD tenofovir disoproxil
fumarate (TDF)/emtricitabine (FTC) in antiretroviral-
naïve, HIV-infected patients.
Methods
Patient selection
Male and non-pregnant female outpatients were eligible
for enrollment if they were ≥ 18 years old, had HIV-1
infection documented by HIV-1 antibody enzyme-linked
immunosorbent assay (ELISA) and Western blot test, were
antiretroviral-naïve (<14 days of antiretroviral treatment),
and were not receiving immunomodulatory drugs.
Women were enrollable if they were postmenopausal,
sterilized, or, if of childbearing potential, had a docu-
mented negative serum or urine pregnancy test (β-human
chorionic gonadotropin) ≤ 7 days of study drug adminis-
tration and used two methods of contraception (barrier
method mandatory).
Study design and treatment
This randomized, open-label, multicenter study was con-
ducted between April 2005 and September 2006 at 16
outpatient sites in the United States. Enrollment was strat-
ified at screening by plasma HIV-1 RNA to one of two
strata (<100,000 and ≥ 100,000 copies/mL). To determine
study eligibility, study candidates underwent a medical
history, physical examination, CDC classification, viral
load, CD4+ counts, clinical chemistry values, liver func-
tion tests, hematology, hepatitis B and C serology, and
serum β-human chorionic gonadotropin test (women of
childbearing age only) at the screening visit within 30
days pre-study. All enrolled patients were randomly
assigned to one of two regimens for 48 weeks:
￿ FPV/r 1400 mg/100 mg QD + TDF 300 mg/FTC 200 mg
QD
￿ ATV/r 300 mg/100 mg QD + TDF 300 mg/FTC 200 mg
QD
FPV/r and TDF/FTC were administered with or without
food and ATV and ritonavir were given together with food.
The FPV dose was given as two 700-mg tablets of Lexiva®
(GlaxoSmithKline, Research Triangle Park, NC), TDF 300
mg/FTC 200 mg as one co-formulated tablet of Truvada®
(Gilead Sciences, Foster City, CA), ritonavir as one 100-
mg soft-gel capsule of Norvir® (Abbott Laboratories, North
Chicago, IL), and ATV as two 150-mg capsules of Reyataz®
(Bristol-Myers Squibb, Princeton, NJ). Patients were
counseled regarding adherence at weeks 0, 4, 12, 24, 36,
and 48, and from the week 4 visit onward they were asked
by study personnel about their level of adherence to each
drug in their regimen.
If patients experienced FPV- or ATV-attributable (per
investigator), treatment-limiting toxicities, they were dis-
continued from the study. If TDF/FTC-attributable, treat-
ment-limiting toxicities occurred, abacavir (ABC) 600 mg/
lamivudine (3TC) 300 mg (Epzicom®, GlaxoSmithKline)
QD could be substituted. No other substitutions were
allowed. All patients provided written informed consent
to participate, and the protocol for the study was
approved by the institutional review boards at each treat-
ment site.
Efficacy assessment
The primary efficacy measure was comparison of the pro-
portion of patients with plasma HIV-1 RNA levels < 50
copies/mL at week 48, with secondary endpoints beingAIDS Research and Therapy 2008, 5:5 http://www.aidsrestherapy.com/content/5/1/5
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proportion with HIV-1 RNA < 50 copies/mL at 24 weeks
and < 400 copies/mL at 24 and 48 weeks; change from
baseline in CD4+ counts at weeks 24 and 48; and HIV
treatment-emergent resistance patterns (described in a
separate paper).
HIV-1 RNA was measured, and change from baseline tab-
ulated, at baseline (week 0), at weeks 4, 12, 24, 36 and 48,
and at withdrawal using the Roche Amplicor MONITOR
Ultrasensitive assay (version 1.5; lower limit of quantita-
tion [LLOQ] 50 copies/mL) (Roche Diagnostics, Branch-
burg, New Jersey) and HIV-1 MONITOR Version 1.0
polymerase chain reaction (PCR) assay (LLOQ, 400 cop-
ies/mL) (Roche, Nutley, New Jersey). Virologic failure was
defined two ways: 1) if prior to week 24, it was defined as
a reduction of plasma HIV-1 RNA level to <50 copies/mL
on two consecutive occasions with a subsequent increase
to ≥ 400 copies/mL on two consecutive occasions 2–4
weeks apart; 2) if it occurred at week 24 or later, virologic
failure was said to have occurred if plasma HIV-1 RNA
level was ≥ 400 copies/mL on two consecutive occasions
2–4 weeks apart. Immunologic response was assessed by
measuring change in CD4+ and CD8+ lymphocyte cell
count from baseline by flow cytometry at weeks 0, 12, 24,
36, 48, and at withdrawal.
Safety assessment
Patients were monitored for adverse events, laboratory
abnormalities, and any HIV-related illnesses at weeks 0, 4,
12, 24, 36, and 48, and at withdrawal. The severity of
adverse events was graded according to DAIDS criteria
[13]. In addition, at weeks 0, 24, and 48, a fasting lipid
panel was done and glomerular filtration rate (GFR) was
estimated by the Modification of Diet in Renal Disease
(MDRD) method [14]. In cases of elevated lipids, hypoli-
pidemic agents could be prescribed at the discretion of the
investigators. However, usage of lovastatin and simvasta-
tin was prohibited, and atorvastatin and fluvastatin were
to be used only on a precautionary basis in view of some
potential for a drug interaction.
Statistical analysis
A sample size of 50 patients per treatment arm was tar-
geted based on practical rather than statistical considera-
tions. No power calculations were made to determine this
sample size. Analyses were performed on the intent-to-
treat: exposed (ITT:E) population, which comprised all
patients exposed to ≥ 1 dose of randomized study medica-
tion. Proportions of patients achieving < 50 copies/mL
(primary efficacy parameter) and <400 copies/mL were
analyzed by an ITT: observed analysis, which included all
observed data, and an ITT: missing/discontinuation = fail-
ure (ITT: MD = F) analysis, in which patients with missing
data or data collected after discontinuation of rand-
omized study medication were considered failures.
Between-treatment comparisons of these proportions
were made by Cochran-Mantel-Haenszel test stratified by
baseline HIV-1 RNA and differences in CD4+ count
changes by Wilcoxon Rank-Sum test. Differences were
considered statistically significant if p was < 0.05. Descrip-
tive statistics alone were applied to all other data compar-
isons, including safety parameters.
Results
Patient characteristics and disposition
One hundred-six patients entered the study and 94 com-
pleted, 45 in the FPV/r100 arm and 49 in the ATV/r100
arm (Table 1). The baseline characteristics of patients in
the two treatment arms were generally similar, except the
FPV/r100 arm included more Caucasians and patients
with a lower baseline CD4+ count. Most (84%) patients
were male, median age was 40 years old, baseline median
HIV-1 RNA was 4.9 log10 copies/mL (45% with ≥ 100,000
copies/mL), and median CD4+ count was 171 cells/
mm3(Table 1). The population was ethnically diverse,
with 40% African Americans, 23% of Hispanic ethnicity.
Baseline MDRD-determined GFR was similar in the FPV/
r100 and ATV/r100 arms (mean, 87.7 and 90.6 mL/min,
respectively), but was 60–89 mL/min in 58% of patients
in both the FPV/r100 arm (31/53) and ATV/r100 arm (31/
53).
The 12 patients who discontinued treatment prematurely
did so for similar reasons, the most common being proto-
col-defined virologic failure. Three patients discontinued
TDF/FTC because their GFR decreased to <50 mL/min,
and TDF/FTC was replaced by ABC/3TC. No patients were
discontinued from the study for non-compliance.
Efficacy
Virologic response
Reduction in HIV-1 RNA was similarly rapid in the FPV/
r100 and ATV/r100 arms, the median decrease from base-
line in HIV-1 RNA at week 4 being 2.2 log10 copies/mL in
each arm. Maximum reduction was seen at week 12 in
both arms, and it remained undiminished through week
48. No significant differences (p  > 0.05) were noted
between the FPV/r100 and ATV/r100 regimens at week 48
(Figure 1) regarding proportion of patients achieving HIV-
1 RNA < 50 copies/mL in the ITT: MD = F analysis (75%
vs 83%) or ITT:observed analysis (89% vs 92%), nor in
the proportion achieving < 400 copies/mL in these analy-
ses (79% vs 87%); 93% vs 96%). Similarly, in patients
with baseline HIV-1 RNA ≥ 100,000 copies/mL, week 48
results showed no differences between the FPV/r100 and
ATV/r100 arms in proportion of patients achieving HIV-1
RNA < 50 copies/mL in the ITT: MD = F analysis (71% vs
75%) or ITT:observed analysis (85% vs 86%), nor in the
proportion achieving < 400 copies/mL in these analyses
(79% vs 79%; 95% vs 90%).AIDS Research and Therapy 2008, 5:5 http://www.aidsrestherapy.com/content/5/1/5
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Virologic failure was observed in similar numbers of
patients in the FPV/r100 and ATV/r100 arms (4 vs 3)
despite the fact that pre-existing resistance to FPV or TDF/
FTC, but not to ATV, was detected at baseline by genotype,
phenotype, or both in 2 patients randomized to the FPV/
r100 arm [15]. None of the 3 failures in the ATV/r100 arm
had pre-existing resistance to ATV or TDF/FTC detected by
population genotype or phenotype at baseline. A full
delineation of resistance data is provided in a separate
paper.
Immunologic response
CD4+ counts showed a similar pattern of increase over the
course of the study in the FPV/r100 and ATV/r100 arms,
with no statistically significant differences in magnitude
of CD4+ count increase at any study visit (Figure 2). At
week 48, the mean increase above baseline in CD4+
counts was 170 cells/mm3 in the FPV/r100 arm and 183
cells/mm3 in the APV/r100 arm (p = 0.398).
Safety
The overall incidence of all adverse events reported by at
least 5% of patients, regardless of attributability to a par-
ticular treatment, is shown in Table 2. The most reported
adverse events in FPV/r100-treated patients were diarrhea
(53% [22/53]), nausea (13% [7/53]), fatigue (4% [2/53]),
and headache (6% [3/53]). In the ATV/r100 arm, diarrhea
(8 [15%]) and nausea (9% [5/53]) were reported less fre-
quently and hyperbilirubinemia (43% [23/53]), ocular
icterus (9% [5/53]), fatigue (8% [4/53]), and jaundice
(6% [3/53]) more frequently (differences in frequency of
adverse events not evaluated for statistical significance).
As for treatment-related adverse events, most were grade 1
or 2 in severity. Evaluation of grade 2–4 treatment-related
adverse events showed that these occurred more fre-
quently in the ATV/r100 arm than in the FPV/r100 arm
(57% vs 15%), driven largely by ATV-related hepatic
effects. Grade 2–4 treatment-related GI adverse events
reported in the FPV/r100 arm were diarrhea in 4 patients
(8%) and nausea in 2 (4%). In the FPV/r100 arm, 1
patient had a grade 3 increased blood phosphorus and
Table 1: Demographic characteristics (ITT exposed population)a and disposition
FPV/r 1400/100 mg + TDF/FTC QD 
N = 53
ATV/r 300/100 mg + TDF/FTC N 
= 53
Total N = 106
Gender, n (%)
Male 42 (79%) 47 (89%) 89 (84%)
Female 11 (21%) 6 (11%) 17 (16%)
Age, y
Median (range) 40 (22–64) 40 (20–58) 40 (20–64)
Race, n (%)b
White 34 (64%) 26 (49%) 59 (56%)
Black 18 (34%) 24 (45%) 42 (40%)
Asian 0 1 (2%) 1 (<1%)
Other 1 (2%) 2 (4%) 2 (2%)
HIV-1 RNA, log10 copies/mL
Median (range) 4.924 (2.775–6.320) 4.890 (3.167–6.362) 4.907 (2.775–6.362)
HIV-1 RNA < 100,000 copies/mL 29 (55%) 29 (55%) 58 (55%)
HIV-1 RNA ≥ 100,000 copies/mL 24 (45%) 24 (45%) 48 (45%)
CD4+ cell count, cells/mm3
Median (range) 161 (19–524) 188 (19–488) 171 (19–524)
CDC classification, n (%)
Class A (asymptomatic) 30 (57%) 34 (64%) 64 (60%)
Class B (symptomatic, non-AIDS) 14 (26%) 8 (15%) 22 (21%)
Class C (AIDS) 9 (17%) 11 (21%) 20 (19%)
Mean GFR (by MDRD), mL/min/
1.73 m2
87.7 (± 20.4) 90.6 (± 18.0)
Study Withdrawals
Completed 45 (85%) 49 (92%) 94 (89%)
Prematurely withdrawn 8 (15%) 4 (8%) 12 (11%)
Reason for premature withdrawal
Adverse event 1 (2%) 1 (2%) 2 (2%)
Lost to follow-up 2 (4%) 0 2 (2%)
Protocol violation 1 (2%) 0 1 (<1%)
Protocol-defined virologic failure 4 (8%) 3 (6%) 7 (7%)
aComprised all patients exposed to ≥ 1 dose of randomized study medication.
b12 patients in the FPV/r arm and 12 in the ATV/r arm were of Hispanic/Latino ethnicity.AIDS Research and Therapy 2008, 5:5 http://www.aidsrestherapy.com/content/5/1/5
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another had hypophosphatemia. Both patients were
among the 3 whose GFR fell below 50 mL/min and who
were withdrawn from the study (see below). Conversely,
in the ATV/r100 arm, grade 3 treatment-related adverse
events included increased blood bilirubin (26% [14/53]),
increased aspartate transaminase (2% [1/53]), increased
triglycerides (2% [1/53]), and hyperbilirubinemia (11%;
6/53]), and grade 4 treatment-related events included
increased bilirubin (2% [1/53]) and increased alanine
transaminase (2% [1/53]).
A similar proportion of patients in each arm experienced
> 25% decrease in MDRD-determined GFR (Figure 3).
Three patients on FPV/r100, but none on ATV/r100, dis-
continued TDF/FTC because their GFR decreased to <50
mL/min. At baseline, none of these patients had co-mor-
bidities likely to account for reduction in GFR. During
treatment, 2 of these 3 patients received no concurrent
drugs known to adversely affect renal function, although
the third began a 6-month course of diclofenac, a non-
steroidal anti-inflammatory agent that has been impli-
cated in rare reports of reduced creatinine clearance [16].
Figure 4 presents median lipid values over the course of
the study, with lines within shaded areas showing NCEP
cut-offs [17]. FPV/r100 and ATV/r100 had comparable
effects on median change from baseline at week 48 in
total-cholesterol (+13 vs +10 mg/dL), LDL-cholesterol (+2
vs -6 mg/dL), and HDL-cholesterol (+11 vs +14 mg/dL).
At week 48, a greater proportion of FPV/r100-treated
patients (50% vs 39%) experienced an elevation in triglyc-
erides that exceeded the NCEP normal range cut-off and,
hence, were categorized as "borderline-high" or "high".
Lipid-lowering agents were used by more patients in the
FPV/r100 arm (n = 7) than in the ATV/r100 arm (n = 1).
These agents included pravastatin (2), atorvastatin (2),
cholestyramine (1), gemfibrozil (1), and nicotinic acid
(1) in the FPV/r100 arm, and atorvastatin (1) in the ATV/
r100 arm. Data contributed from patients after starting
lipid-lowering agents were censored from the analysis.
Discussion
In this study, the FPV/r100 and ATV/r100 arms performed
similarly well with respect to virologic suppression and
CD4+ cell enhancement. High virologic efficacy with the
FPV/r100 regimen was expected based on the results of
two other small clinical efficacy trials evaluating FPV/
Proportion of patients with HIV-1 RNA < 400 copies/mL and < 50 copies/mL (intent-to-treat: missing/discontinuation = failure  analysis) Figure 1
Proportion of patients with HIV-1 RNA < 400 copies/mL and < 50 copies/mL (intent-to-treat: missing/discon-
tinuation = failure analysis).
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r100-containing regimens [18,19]. Hicks et al [18]
reported that at 48 weeks, the proportion of ART-naïve
patients (baseline median HIV-1 RNA 4.8 log10 copies/
mL, CD4+ count 190 cells/mm3) able to achieve HIV-1
RNA levels < 50 copies/mL was as high or higher (depend-
ing on the type of analysis method), with an FPV/r100-
containing QD regimen + ABC/3TC than with a FPV/r200-
containing QD regimen with the same nucleoside back-
bone (79% vs 63% [ITT: M = F analysis], 92% vs 80%
[observed analysis]). DeWit et al [19] evaluated FPV/r100
+ TDF + 3TC (n = 57) (or FTC n = 19]) in ART-naïve
patients (baseline median HIV-1 RNA 4.9 log10 copies/
mL, CD4+ count 171 cells/mm3) and noted that at 48
weeks, 86% had HIV-1 RNA < 50 copies/mL (ITT: M = F)
and CD4+ counts had increased above baseline by a
median of 268 cells/mm3. TELEX II reported that patients
stabilized (HIV-1 RNA < 50 copies/mL) for 48 weeks on
FPV/r200 QD plus TDF/FTC 300/200 mg QD remained
Mean CD4+ cell counts at all study visits Figure 2
Mean CD4+ cell counts at all study visits.
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Table 2: All adverse events reported by frequency >5%
FPV/r 1400/100 mg + TDF/FTC QD N = 53 ATV/r 300/100 mg + TDF/FTC QD N = 53
Diarrhea 28 (53%) 13 (25%)
Blood bilirubin increased 0 16 (30%)
Nausea 8 (15%) 6 (11%)
Rash 9 (17%) 5 (9%)
Fatigue 6 (11%) 7 (13%)
Headache 5 (9%) 3 (6%)
Hyperbilirubinemia 0 8 (15%)
Cough 4 (8%) 3 (6%)
Nasopharyngitis 3 (6%) 4 (8%)
Upper respiratory tract infection 2 (4%) 4 (8%)
Arthralgia 0 5 (9%)
Insomnia 2 (4%) 3 (6%)
Ocular icterus 0 5 (9%)
Syphilis 5 (9%) 0
Depression 3 (6%) 1 (2%)
Herpes zoster 1 (2%) 3 (6%)
Dizziness 3 (6%) 0
Jaundice 0 3 (6%)
Paresthesia 3 (6%) 0AIDS Research and Therapy 2008, 5:5 http://www.aidsrestherapy.com/content/5/1/5
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stabilized 4 weeks after reducing the ritonavir boosting
dose to 100 mg QD [10].
The FPV/r100 regimen also is justified by four pharma-
cokinetic studies that reported little or no difference in the
APV Cmin or AUC exposure in patients treated with FPV/
r100 and FPV/r200 QD [5,9-11], possibly because ritona-
vir at 100 mg appears to predominantly inhibit CYP3A4
metabolism of APV, whereas ritonavir at 200 mg may
have a combination of CYP3A4 inhibitory and induction
effects [20]. As of October 12, 2007, ritonavir 100 mg QD
boosting of FPV dosing was approved by the FDA [21] and
listed as an alternative regimen in the DHHS HIV treat-
ment guidelines [22]. Current International AIDS Society
(IAS) treatment guidelines recommend ritonavir-boosted
FPV as a recommended PI-based treatment for the initial
treatment of HIV infection [23] and the British HIV Asso-
ciation (BHIVA) treatment guidelines list ritonavir-
boosted FPV as an alternative first-line regimen [24].
The efficacy of the ATV/r100 regimen observed in our
study was comparable to that reported in SHARE, which
evaluated ATV/r100 + ABC/3TC in 111 ART-naïve patients
(baseline median HIV-1 RNA 5.06 log10 copies/mL, CD4+
count 207 cells/mm3) [25]. At 48 weeks, 77% of ATV/
r100-treated patients in SHARE achieved HIV-1 RNA < 50
copies/mL by ITT: M = F analysis and 90% by ITT:
observed analysis, and their CD4+ cell count increased
above baseline by a median of 188 cell/mm3. Inclusion of
a 100-mg dose of ritonavir was important in the ATV reg-
imen to counteract the previously documented TDF-
related 23% reduction in ATV Cmin and 25% reduction in
ATV exposure that is believed to be due to a physicochem-
ical interaction of ATV and TDF in the intestine [26]. As
ritonavir 100 mg increases ATV Cmin by 3-fold higher than
is attainable with unboosted ATV 400 mg QD, this dose
compensates for the negative pharmacokinetic effects of
TDF [7]. As of January 2008, ATV/r100-based regimens are
considered first-line PI regimens by DHHS HIV treatment
guidelines [21], as recommended PI regimens by IAS
guidelines [23], and as alternative PI regimens by BHIVA
guidelines [24].
Grade 2–4 treatment-related adverse GI effects with FPV/
r100 were observed, but the incidence was generally lower
than has been reported with FPV boosted by r200 QD
[5,18]. Thus, when a direct comparison of FPV/r100 vs
FPV/r200 regimens was done in ART-naïve patients, the
FPV/r100 regimen showed less grade 2–4 nausea (3% vs
5%) and diarrhea (14% vs 18%) [18]. Similarly, where
such a comparison was made in healthy volunteers, a
lower frequency of nausea (11% vs 27%) and loose stools
(22% vs 29%) was also reported [5]. The high incidence
of increased bilirubin in the ATV group was expected, as
this has been described in previous ATV/r studies [27,28].
Fifty-eight percent of our patients entered the trial with
GFR < 90 mL/min (31 in the ATV/r100 arm and 19 in the
Proportion of patients with change in MDRD-determined glomerular filtration rate from baseline to week 48 Figure 3
Proportion of patients with change in MDRD-determined glomerular filtration rate from baseline to week 48.
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FPV/r100 arm), indicating some level of renal dysfunction
pre-study in a substantial proportion of the study popula-
tion. GFR changes were noted in both treatment arms,
and reduction in GFR to below 50 mL/min resulted in 3
patients needing to be discontinued from the trial. Phar-
macokinetic studies have established a drug-drug interac-
tion between some PI's and TDF resulting in increased
tenofovir concentrations [29-32]. Other data have sug-
gested that diminished TDF renal tubule efflux is respon-
sible for increased TDF concentrations within renal cells
and plasma [33]. This finding has been postulated as a
potential explanation for the decreased GFR seen in some
patients treated with boosted PI's and TDF [34,35]. The
boosted PIs ATV, lopinavir, saquinavir, and darunavir
have been associated with an increase in tenofovir con-
centrations during co-administration [29-32], whereas
this has not been observed with fosamprenavir (boosted
and unboosted), indinavir (unboosted), tipranavir
(boosted), and nelfinavir (unboosted) [31,36-38].
Wai et al [39] noted that the incidence of TDF-related GFR
reduction is greater when RTV is administered concur-
rently in TDF-based regimens. This underscores the
importance of achieving maximal boosting with the low-
est possible RTV dose. As some factors that can contribute
to renal decline in patients may not be known when they
initially seek treatment, it is advisable that when a TDF/
FTC backbone is being considered for use with PI-based
therapy, renal function should be assessed at baseline and
throughout treatment.
The magnitude of elevated total cholesterol, LDL-choles-
terol, and especially triglycerides observed in the FPV/
r100 arm was lower than has been reported with FPV/r
1400/200 mg QD regimens [12]. Median increase in
HDL-cholesterol levels, a lipid change associated with
reduction in cardiac risk, was observed in this study just as
it has been in all other studies evaluating FPV/r100
[10,18]. A favorable change in lipid profile while main-
taining clinical efficacy also has been reported within 4
weeks after ART-naïve patients were switched from FPV/
r200 + TDF/FTC to FPV/r100 + TDF/FTC [10]. Where FPV/
r100- and FPV/r200-containing regimens have been
directly compared over 48 weeks, no major differences in
Median lipid values over the course of the study, with lines within shaded areas showing NCEP cut-offs Figure 4
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lipid profiles were seen in one study (and no greater lipid
effects at 48 weeks compared to 24 weeks) [18], whereas
in the other study, FPV/r100 was associated with a less
pronounced rise in triglycerides [5]. Although our study
showed that the triglyceride increase at week 48 exceeded
the NCEP cut-off in 50% of FPV/r100 vs 39% of ATV/r100
patients, they remained normal or just borderline high for
most patients. In view of the minor lipid changes
observed over 48 weeks with FPV/r 1400/100 mg QD, lit-
tle or no lipid advantage was apparent for the ATV/r regi-
men.
This study is the first head-to-head clinical trial to com-
pare FPV/r100- and ATV/r100-based regimens. The pri-
mary limitation of the study was its small sample size as it
was done on a pilot basis. The study provides useful infor-
mation since the study population was diverse with
respect to gender, race, and ethnicity and mirrors the pop-
ulation where the epidemic is seen today.
Conclusion
In conclusion, this pilot study showed that all-QD FPV/
r100 and ATV/r100, in combination with TDF/FTC, pro-
vided similar virologic suppression and CD4+ cell
increases through 48 weeks. A lower percentage of FPV/
r100-treated patients experienced treatment-related grade
2–4 adverse events, and total/LDL/HDL cholesterol
changes were generally similar.
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